PRT062607 (P505-15) HCl

CAS : 1370261-97-4

Ref. 3D-VEC26197

Informations sur le produit

• Nom: PRT062607 (P505-15) HCl
• Synonymes: 2-[[(1R,2S)-2-Aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-5-pyrimidinecarboxamide Hydrochloride, 2-{[(1R,2R)-2-Aminocyclohexyl]amino}-4-{[3-(2H-1,2,3-triazol-2-yl )phenyl]amino}-5-pyrimidinecarboxamide hydrochloride (1:1), 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-((1R,2S)-2-aminocyclohexylamino)pyrimidin-5-carboxamide hydrochloride, 4-(3-([1,1'-Biphenyl-4-Yl])-3-Oxopropyl)Benzonitrile, 5-Pyrimidinecarboxamide, 2-[[(1R,2S)-2-aminocyclohexyl]amino]-4-[[3-(2H-1,2,3-triazol-2-yl)phenyl]amino]-, hydrochloride (1:1), Benzonitrile,4-(3-[1,1'-biphenyl]-4-yl-3-oxopropyl), P505-15, BIIB057 HCl, PRT062607(HCL), PRT062607(Hydrochloride)
• CAS: 1370261-97-4

Description

PRT062607 is a compound that has been shown to inhibit pro-inflammatory cytokine production. It binds to the PD-L1 protein and blocks the interaction of PD-1 with its ligands, TNFα, IL-6, and IL-12. This leads to an increase in apoptosis of cancer cells. PRT062607 is also a potent inhibitor of inflammatory bowel disease in mice. The compound has been tested on primary cells from human small intestine and colon. In cell signaling pathway studies, it was found that PRT062607 inhibits NFκB activation. This inhibition leads to reduced inflammation and decreased levels of pro-inflammatory cytokines such as IL-6 and TNFα. In addition, PRT062607 has been shown to be effective against infectious diseases such as Helicobacter pylori infection in humans.
PRT062607 (P505-15) HCl is a chemical compound that belongs to the group of pept

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 429.91 g/mol
• Formule: C₁₉H₂₃N₉O·HCl
• Degré de pureté: Min. 95%